Cite
413PClinical benefits of later line trabectedin and eribulin treatment for soft tissue sarcoma (STS) after pazopanib treatment from the Nishinomiya Sarcoma Cohort Study (NSCS).
MLA
Narahara, H., et al. “413PClinical Benefits of Later Line Trabectedin and Eribulin Treatment for Soft Tissue Sarcoma (STS) after Pazopanib Treatment from the Nishinomiya Sarcoma Cohort Study (NSCS).” Annals of Oncology, vol. 29, Nov. 2018, p. N.PAG. EBSCOhost, https://doi.org/10.1093/annonc/mdy443.007.
APA
Narahara, H., Morimoto, M., Tanaka, E., Ueda, S., Yasunaga, Y., Inui, Y., Takahashi, K., & Kawata, S. (2018). 413PClinical benefits of later line trabectedin and eribulin treatment for soft tissue sarcoma (STS) after pazopanib treatment from the Nishinomiya Sarcoma Cohort Study (NSCS). Annals of Oncology, 29, N.PAG. https://doi.org/10.1093/annonc/mdy443.007
Chicago
Narahara, H, M Morimoto, E Tanaka, S Ueda, Y Yasunaga, Y Inui, K Takahashi, and S Kawata. 2018. “413PClinical Benefits of Later Line Trabectedin and Eribulin Treatment for Soft Tissue Sarcoma (STS) after Pazopanib Treatment from the Nishinomiya Sarcoma Cohort Study (NSCS).” Annals of Oncology 29 (November): N.PAG. doi:10.1093/annonc/mdy443.007.